Authors
Latest:
Dr. Woyach on Clinical Trials Examining Novel Triplets in CLLJennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.
Latest:
Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer TreatmentJennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.
Latest:
Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLLJennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.
Latest:
Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLCJennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.
Latest:
Dr. Chan on Trial of Cabozantinib in Neuroendocrine TumorsJennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).
Latest:
Dr Amengual on Tazemetostat, Lenalidomide, and Rituximab in Relapsed/Refractory FLJennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).
Latest:
Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ AdenocarcinomaJennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.
Latest:
Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBCJennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.
Latest:
Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer PatientOncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.
Latest:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationAmgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Latest:
Deciding When Post-Mastectomy Radiation Therapy Is WarrantedFor appropriate patients, postmastectomy radiation therapy is associated with improved locoregional control and better survival.
Latest:
Strategies for Lung Cancer Screening Implementation: Program Structure and Panel ProfilesThe structure of lung cancer screening programs in the United States vary by resource availability, provider expertise, type of institution, and interests of the organization. Often these programs are developed through the reorganization of preexisting multidisciplinary models that have been providing services related to lung cancer.
Latest:
Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast CancerBreast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.
Latest:
Tackling Patient Recruitment Challenges in Clinical TrialsPatients fear being a "guinea pig" or receiving a placebo, healthcare providers do not have time to keep up with all of the clinical trial information or talk with patients in depth, conducting clinical trials is very expensive for healthcare systems, and funding continues to decline for research.
Latest:
Dr. Ligibel Discusses Lifestyle Intervention in Breast CancerJennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses lifestyle intervention in the treatment of patients with breast cancer.
Latest:
Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBCJennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.
Latest:
Opening the Door for Novel Therapies in Triple-Negative Breast CancerDuring a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.
Latest:
Microbiome Emerges as a Hot Topic in Cancer ResearchResearchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.
Latest:
Dr. Kapo on Addressing Palliative Care With PatientsJennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.
Latest:
Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in MelanomaJennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.
Latest:
Dr. Montes on the Relationship of MRI Imaging Characteristics With RaceJennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.
Latest:
Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell MalignanciesJennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
Latest:
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Latest:
Rapid Readouts: First interim analysis of the ALPINE study: a phase III randomized trial of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer R. Brown, MD, PhD presents an interim analysis from the ALPINE study of zanubrutinib vs. ibrutinib in patients with R/R CLL/SLL presented at the 2021 European Hematology Association virtual congress.
Latest:
Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic TelangiectasiaHematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.
Latest:
Managing the Side Effects of Androgen-Deprivation TherapyAndrogen-deprivation therapy (ADT) is a widely accepted treatment for men with advanced or metastatic prostate cancer.
Latest:
Trials Show Efficacy of PARP-Targeted Agent in Prostate CancerDrugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.
